Mechanism of action
Sulfinpyrazone is a classic example of uricosuric agents, a pharmacological group of drugs whose action aims to increase uric acid excretion from the body. It is important to understand the fundamental difference of this group: the drugs do not block uric acid synthesis itself (unlike synthesis inhibitors), but interfere exclusively with its renal excretion processes.
At the cellular level, the mechanism of action of Sulfinpyrazone consists in direct competition with uric acid molecules for specific transport systems located in the renal tubules. The drug causes selective blockade of urate reabsorption (their uptake). The site of action is predominantly the distal segments of the nephron. As a result of this pharmacological blockade, uric acid loses its ability to return into the systemic circulation, which naturally leads to a significant increase in its excretion with urine.
Pharmacological effects and indications
The key pharmacological effect of Sulfinpyrazone is a sustained decrease in plasma uric acid levels.
In clinical practice, the drug is used for chronic treatment, i.e., long-term prevention of attacks of diseases accompanied by hyperuricemia. By lowering plasma urate concentration, the drug prevents their deposition in tissues, thereby minimizing the risks of new acute attacks. Uricosuric agents are not used to relieve an already developed acute attack; their main goal is systematic control of blood urate levels.
Side effects
The use of Sulfinpyrazone requires careful monitoring of the patient's condition due to the risk of serious adverse reactions affecting various organ systems:
- Hematotoxicity: the drug can have a suppressive effect on the hematopoiesis system. This may manifest as agranulocytosis, leukopenia, thrombocytopenia, and anemia. Patients require regular monitoring of complete blood counts.
- Dyspeptic disorders: nausea and marked abdominal pain are frequently observed from the gastrointestinal tract.
- Risk of kidney stone formation: since the drug forces the excretion of uric acid, its concentration in the renal filtrate sharply increases. This creates a direct threat of urate crystallization directly in the urinary tract with subsequent stone formation.
Prescribing features and prevention of complications
The drug is available in 0.1 g tablets. It is prescribed orally, with a standard regimen of 0.1 g 4 times a day. It is strictly recommended to take the drug with meals, which helps reduce the risk of the dyspeptic disorders described above.
To prevent the most formidable complication—uric acid crystallization in the renal filtrate—therapy with Sulfinpyrazone must be accompanied by two mandatory preventive measures:
- High fluid intake: necessary for mechanical increase in urine volume and decrease in urate concentration in the renal tubules.
- Urinary alkalinization: patients are additionally prescribed agents that shift urine pH toward the alkaline side (e.g., potassium citrate). In an alkaline environment, uric acid solubility increases significantly, preventing crystal formation.
Briefly: answers to topical questions
Why is sulfinpyrazone not used to relieve an acute gout attack?
Sulfinpyrazone is intended for attack prevention as part of chronic treatment aimed at lowering plasma uric acid levels. The drug belongs to uricosuric agents, which increase uric acid excretion rather than block its synthesis.
The mechanism of action includes:
- Competition — interaction with uric acid for transport systems in the renal tubules.
- Reabsorption blockade — suppression of urate reabsorption in the distal nephron, leading to increased urinary excretion.
Sulfinpyrazone is a "Super Renal Filter": it does not inhibit urate synthesis, but forces the kidneys to actively filter and excrete them by competing for transport systems.
Class and exam questions
What is the fundamental difference between Sulfinpyrazone and Allopurinol?
Allopurinol and Febuxostat are uric acid synthesis inhibitors. Sulfinpyrazone (like Probenecid or Benzbromarone) belongs to uricosuric agents: it does not interfere with synthesis, but increases the excretion of already formed uric acid.
Why is urine alkalinization mandatory when prescribing the drug?
The drug sharply increases the concentration of uric acid in the renal filtrate, posing a risk of kidney stone formation. Urine alkalinization (e.g., with potassium citrate) increases urate solubility and prevents their crystallization.
What changes in the complete blood count does Sulfinpyrazone cause?
The drug has pronounced hematotoxicity. It can cause suppression of hematopoiesis, manifested as agranulocytosis, leukopenia, thrombocytopenia, or anemia.
What else to study on this topic
- Renal tubular transport systems: physiology of urate secretion and reabsorption.
- Comparative pharmacodynamics of uricosuric agents (Sulfinpyrazone, Probenecid, Benzbromarone).
- Uric acid synthesis inhibitors: mechanism of action of Allopurinol and Febuxostat.
- Drug hematotoxicity: pathogenesis of drug-induced agranulocytosis.
- Principles of medical urine alkalinization and prevention of urate nephrolithiasis.
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Sulfinpyrazone" and 5,304 more subject pages
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the «Drugs and Prescriptions» section
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.